Brief: Eql Pharma Says Sales In Q2 Are Expected To Land Just Under 90 (85.2) MSEK

EQL Pharma AB

22/09/2025 21:38

Sept 22 (Reuters) - EQL Pharma AB EQL.ST:

DELIVERY DELAYS MEAN THAT THE SECOND QUARTER AND THUS THE FULL YEAR 2025/26 WILL BE WEAKER THAN EXPECTED

EQL PHARMA AB: EBITDA MARGIN CLOSER TO 20 THAN 25 PERCENT IS EXPECTED FOR FULL YEAR 2025/26

EQL PHARMA AB - SALES IN Q2 ARE EXPECTED TO LAND JUST UNDER 90 (85.2) MSEK

Source text: ID:nWkr31w26S

Further company coverage: EQL.ST

 ((Reuters.Briefs@thomsonreuters.com;))